Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2017

01-02-2017 | Original Article

Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors

Authors: Etsuko Miyagi, Yasuyo Maruyama, Tae Mogami, Reiko Numazaki, Atsuko Ikeda, Hiroshi Yamamoto, Fumiki Hirahara

Published in: International Journal of Clinical Oncology | Issue 1/2017

Login to get access

Abstract

Background

We previously developed a new plasma amino acid profile-based index (API) to detect ovarian, cervical, and endometrial cancers. Here, we compared API to serum cancer antigen 125 (CA125) for distinguishing epithelial ovarian malignant tumors from benign growths.

Methods

API and CA125 were measured preoperatively in patients with ovarian tumors, which were later classified into 59 epithelial ovarian cancers, 21 epithelial borderline malignant tumors, and 97 benign tumors including 40 endometriotic cysts. The diagnostic accuracy and cutoff points of API were evaluated using receiver operating characteristic (ROC) curves.

Results

The area under the ROC curves showed the equivalent performance of API and CA125 to discriminate between malignant/borderline malignant and benign tumors (both 0.77), and API was superior to CA125 for discrimination between malignant/borderline malignant lesions and endometriotic cysts (API, 0.75 vs. CA125, 0.59; p < 0.05). At the API cutoff level of 6.0, API and CA125 had equal positive rates of detecting cancers and borderline malignancies (API, 0.71 vs. CA125, 0.74; p = 0.84) or cancers alone (API, 0.73 vs. CA125, 0.85; p = 0.12). However, API had a significantly lower detection rate of benign endometriotic cysts (0.35; 95 % CI, 0.21–0.52) compared with that of CA125 (0.65; 95 % CI, 0.48–0.79) (p < 0.05).

Conclusions

API is an effective new tumor marker to detect ovarian cancers and borderline malignancies with a low false-positive rate for endometriosis. A large-scale prospective clinical study using the cutoff value of API determined in this study is warranted to validate API for practical clinical use.
Literature
1.
2.
3.
Yamagami W, Aoki D (2015) Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res 41:1861–1869CrossRefPubMed
4.
Lu KH, Skates S, Hernandez MA et al (2013) A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer (Phila) 119:3454–3461CrossRef
5.
6.
7.
Jacobs I, Stabile I, Bridges J et al (1988) Multimodal approach to screening for ovarian cancer. Lancet 8580:268–271CrossRef
8.
Menon U, Talaat A, Rosenthal AN et al (2014) Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 121(suppl 7):35–39CrossRefPubMed
9.
Rocconi RP, Matthews KS, Kemper MK et al (2009) The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 114:242–245CrossRefPubMed
10.
Cascino A, Muscaritoli M, Cangiano C et al (1995) Plasma amino acid imbalance in patients with lung and breast cancer. Anti-Cancer Res 15:507–510
11.
Kubota A, Meguid MM, Hitch DC (1992) Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer (Phila) 69:2343–2348CrossRef
12.
Miyagi Y, Higashiyama M, Gochi A et al (2011) Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 6:e24143CrossRefPubMedPubMedCentral
13.
Okamoto N (2012) Use of “AminoIndex technology” for cancer screening (in Japanese). Ningen Dock 26:911–922
14.
Ihata Y, Miyagi E, Numazaki R et al (2014) Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker. Int J Clin Oncol 19:364–372CrossRefPubMed
15.
Fukutake N, Ueno M, Hiraoka N et al (2015) A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS One 10:e0132223CrossRefPubMedPubMedCentral
16.
Miyagi E, Numazaki R, Nakanishi T et al (2012) Diagnostic performance and clinical utility of novel gynecologic cancer screening method based on “Aminoindex Technology” (in Japanese). Ningen Dock 26:749–755
17.
Shimbo K, Oonuki T, Yahashi A et al (2009) Precolumn derivatization reagents for high-speed analysis of amines and amino acids in biological fluid using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 23:1483–1492CrossRefPubMed
18.
Shimbo K, Yahashi A, Hirayama K et al (2009) Multifunctional and highly sensitive precolumn reagents for amino acids in liquid chromatography/tandem mass spectrometry. Anal Chem 81:5172–5179CrossRefPubMed
19.
Shimbo K, Kubo S, Harada Y et al (2010) Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography/mass spectrometry. Biomed Chromatogr 24:683–691CrossRefPubMed
20.
Proenza AM, Oliver J, Palou A et al (2003) Breast and lung cancer are associated with a decrease in blood cell amino acid content. J Nutr Biochem 14:133–138CrossRefPubMed
21.
Okamoto N, Miyagi Y, Chiba A et al (2009) Diagnostic modeling with differences in plasma amino acid profiles between non-cachectic colorectal/breast cancer patients and healthy individuals. Int J Med Med Sci 1:1–8
22.
Maeda J, Higashiyama M, Imaizumi A et al (2010) Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 10:690CrossRefPubMedPubMedCentral
23.
Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34:137–143CrossRefPubMed
24.
Suzuki Y, Suda T, Furuhashi K et al (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67:361–365CrossRefPubMed
25.
26.
Kadan Y, Fiascone S, McCourt C et al (2015) Predictive factors for the presence of malignant transformation of pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol 185:23–27CrossRefPubMed
27.
Jacobs IJ, Menon U, Ryan A et al (2015) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomized controlled trial. Lancet 10022:945–956
28.
Haruta S, Furukawa N, Yoshizawa Y et al (2011) Molecular genetics and epidemiology of epithelial ovarian cancer. Oncol Rep 26:1347–1356PubMed
Metadata
Title
Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors
Authors
Etsuko Miyagi
Yasuyo Maruyama
Tae Mogami
Reiko Numazaki
Atsuko Ikeda
Hiroshi Yamamoto
Fumiki Hirahara
Publication date
01-02-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1035-4

Other articles of this Issue 1/2017

International Journal of Clinical Oncology 1/2017 Go to the issue

Review Article

T-cell lymphomas, a challenging disease: types, treatments, and future

Original Article

Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers

Original Article

Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy

Original Article

Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma

Original Article

The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy

Original Article

The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits